HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) (HLA-DRA)

HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) is a critical component of the Major Histocompatibility Complex (MHC) class II heterodimer, which plays a central role in the adaptive immune system by presenting exogenous peptides to CD4+ T cells. Primarily expressed on professional antigen-presenting cells such as B cells, macrophages, and dendritic cells, HLA-DRA pairs with various DR beta chains to form the functional HLA-DR receptor. The expression levels of this molecule are vital clinical indicators; for example, decreased monocyte HLA-DR expression is a recognized biomarker for immune paralysis in sepsis and trauma, while high expression in certain solid tumors is often associated with improved patient prognosis and response to immunotherapy. In therapeutic contexts, HLA-DRA is a target for monoclonal antibodies in oncology and its expression is modulated by cytokines like Interferon-gamma to boost immune surveillance. Conversely, many immunosuppressive drugs, such as corticosteroids and calcineurin inhibitors, function by downregulating the expression of MHC class II molecules to prevent transplant rejection or treat autoimmune flares. Consequently, HLA-DRA serves as both a therapeutic target for immune modulation and a primary biomarker for monitoring host immune competence in clinical settings.

Other names

HLA-DRA1MHC class II antigen DRAMLRWMajor histocompatibility complex, class II, DR alphaHLA class II histocompatibility antigen, DR alpha chain

Modulation of MHC class II expression or direct binding to the HLA-DR complex to alter antigen presentation and T-cell activation.